PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling

Molecular Cancer

Research

Yong Q Chen¹  M Katie Conley-LaComb²  Pridvi Kandagatla²  Allen Saliganan²  Sreenivasa R Chinni³  Michael L Cher³ 

[1] Department of Cancer Biology, Wake Forest University, 27157, Winston-Salem, NC, USA;Departments of Urology and Pathology, Wayne State University School of Medicine, 9245 Scott Hall 540 E. Canfield Avenue, 48201, Detroit, MI, USA;Departments of Urology and Pathology, Wayne State University School of Medicine, 9245 Scott Hall 540 E. Canfield Avenue, 48201, Detroit, MI, USA;The Barbara Ann Karmanos Cancer Institute, Wayne State University, 48201, Detroit, MI, USA;

关键词: DU145 Cell;    CXCR4 Expression;    Human Prostate Cancer Cell;    PTEN Loss;    Trabecular Bone Area;   

DOI  :  10.1186/1476-4598-12-85

 received in 2013-04-12, accepted in 2013-07-01,  发布年份 2013

来源: Springer

【 摘 要 】

IntroductionThe chemokine CXCL12, also known as SDF-1, and its receptor, CXCR4, are overexpressed in prostate cancers and in animal models of prostate-specific PTEN deletion, but their regulation is poorly understood. Loss of the tumor suppressor PTEN (phosphatase and tensin homolog) is frequently observed in cancer, resulting in the deregulation of cell survival, growth, and proliferation. We hypothesize that loss of PTEN and subsequent activation of Akt, frequent occurrences in prostate cancer, regulate the CXCL12/CXCR4 signaling axis in tumor growth and bone metastasis.MethodsMurine prostate epithelial cells from PTEN+/+, PTEN+/−, and PTEN−/− (prostate specific knockdown) mice as well as human prostate cancer cell lines C4-2B, PC3, and DU145 were used in gene expression and invasion studies with Akt inhibition. Additionally, HA-tagged Akt1 was overexpressed in DU145, and tumor growth in subcutaneous and intra-tibia bone metastasis models were analyzed.ResultsLoss of PTEN resulted in increased expression of CXCR4 and CXCL12 and Akt inhibition reversed expression and cellular invasion. These results suggest that loss of PTEN may play a key role in the regulation of this chemokine activity in prostate cancer. Overexpression of Akt1 in DU145 resulted in increased CXCR4 expression, as well as increased proliferation and cell cycle progression. Subcutaneous injection of these cells also resulted in increased tumor growth as compared to neo controls. Akt1 overexpression reversed the osteosclerotic phenotype associated with DU145 cells to an osteolytic phenotype and enhanced intra-osseous tumor growth.ConclusionsThese results suggest the basis for activation of CXCL12 signaling through CXCR4 in prostate cancer driven by the loss of PTEN and subsequent activation of Akt. Akt1-associated CXCL12/CXCR4 signaling promotes tumor growth, suggesting that Akt inhibitors may potentially be employed as anticancer agents to target expansion of PC bone metastases.

【 授权许可】

Unknown   
© Conley-LaComb et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.